Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 3/20 | 0.62 |
| ▸ | NPY2R | P49146 | 3/20 | 0.62 |
| ▸ | NPY4R | P50391 | 3/20 | 0.62 |
| ▸ | CTSB | P07858 | 2/20 | 0.60 |
| ▸ | CTSK | P43235 | 2/20 | 0.60 |
| ▸ | PCSK9 | Q8NBP7 | 2/20 | 0.56 |
| ▸ | NPBWR1 | P48145 | 3/20 | 0.54 |
| ▸ | MAGI3 | Q5TCQ9 | 1/20 | 0.54 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.53 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.53 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.53 |
| ▸ | GHSR | Q92847 | 1/20 | 0.52 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.51 |
| ▸ | CDK2 | P24941 | 2/20 | 0.51 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.51 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30887369 | 0.93 | CTSB (0.64) | NPY1RNPY2RNPY4RCTSBCTSK | |
| SCHEMBL29679796 | 0.92 | PCSK9 (0.62) | NPY1RNPY2RNPY4RCTSBCTSK | |
| SCHEMBL29471300 | 0.90 | CTSB (0.60) | NPY1RNPY2RNPY4RCTSBCTSK | |
| SCHEMBL29426680 | 0.88 | NPY1R (0.68) | NPY1RNPY2RNPY4RERAP2ERAP1 | |
| SCHEMBL29573751 | 0.87 | NPY1R (0.60) | NPY1RNPY2RNPY4RCTSBCTSK | |
| SCHEMBL30130581 | 0.87 | EDNRA (0.59) | CTSBCTSKPCSK9NPBWR1MAGI3 | |
| SCHEMBL29847744 | 0.85 | MAGI3 (0.53) | PCSK9MAGI3GHSR | |
| SCHEMBL29547373 | 0.85 | CTSB (0.61) | NPY1RNPY2RNPY4RCTSBCTSK | |
| SCHEMBL30345213 | 0.84 | GHSR (0.60) | NPY1RNPY2RNPY4RCTSBCTSK | |
| SCHEMBL29496441 | 0.84 | GHSR (0.65) | NPY1RNPY2RNPY4RGHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12564617-B2 | Methods for modulating macrophage activity | Riptide Bioscience, Inc. (US) | 2026-03-03 | — | — | US | disclosed |
| US-20220062373-A1 | Methods for Modulating Macrophage Activity | Riptide Bioscience, Inc. | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12564617-B2 | Methods for modulating macrophage activity | MSR1, CSF1R, CD209 | NPY1R 166/4885NPY2R 209/4885NPY4R 390/4885 |
| US-20220062373-A1 | Methods for Modulating Macrophage Activity | CD209, CD68, CD14 | NPY1R 604/4885NPY2R 627/4885NPY4R 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.